Summit Therapeutics announces data from Phase III HARMONi trial

Summit Therapeutics (SMMT) announced data from the Phase III HARMONi trial featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab. The data was presented this morning as part of the Presidential Symposium at the International Association for the Study of Lung Cancer’s, IASLC, 2025 World Conference on Lung Cancer, WCLC 2025, in Barcelona, Spain. The HARMONi presentation, Ivonescimab vs Placebo Plus Chemo, Phase 3 in Patients with EGFR+ NSCLC Progressed with 3rd gen EGFR-TKI Treatment: HARMONi, evaluated ivonescimab plus platinum-doublet chemotherapy compared to placebo plus platinum-doublet chemotherapy in patients with epidermal growth factor receptor-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer who have progressed after treatment with a 3rd generation EGFR tyrosine kinase inhibitor. This is a clinical setting with a patient population where PD-1 monoclonal antibodies have previously been unsuccessful in Phase III global clinical trials in showing either a progression-free survival or overall survival benefit, the two primary endpoints of this clinical study.